MEDICAMENTOS EN ESPAÑA 482 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Sarclisa® (isatuximab). 2020. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/1201435001/ FT_1201435001.pdf. Arcuri LJ, Americo AD. Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. Ann Hematol. 2021; 100(3): 725-34. DOI: 10.1007/s00277-021-04404-3. European Medicines Agency (EMA). Sarclisa®. European Public Assessment Report (EPAR). 2020. EMA/CHMP/200978/2020. Disponible en: https://www.ema.europa.eu/en/documents/assessment-report/sarclisa-epar-public-assessment-report_en-0.pdf. European Medicines Agency (EMA). Sarclisa®. European Public Assessment Report – Variation. 2021. EMA/CHMP/186236/2021. Disponible en: https://www.ema.europa.eu/en/documents/variation-report/sarclisa-h-c-004977-ii-0003-epar-assessment-reportvariation_en.pdf. Fernández Moriano C. Mieloma múltiple. Panorama Actual Med. 2020; 44(435): 751-78. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019; 37(14): 1228-63. DOI: 10.1200/JCO.18.0209. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292): 2361-71. DOI: 10.1016/ S0140-6736(21)00592-4. Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F et al. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncol. 2021; 17(34): 4797-812. DOI: 10.2217/ fon-2021-0568. Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022; 23(3): 416-27. DOI: 10.1016/S1470-2045(22)00019-5. Sociedad Española de Hematología y Hemoterapia. Isatuximab + carfilzomib + dexametasona en mieloma múltiple refractario o en recidiva. Informe de posición de la SEHH. 2021. Disponible en: https://www.sehh.es/publicaciones/informes-de-posicion-de-la-sehh-ips/124615-isatuximab-carfilzomib-dexametasona-en-mieloma-multiple-refractario-o-en-recidiva. Bibliografía Isatuximab en mieloma múltiple
RkJQdWJsaXNoZXIy MTEwMTU=